@article {Roman2021.05.21.21257595, author = {Yuani M. Roman and Paula Alejandra Burela and Vinay Pasupuleti and Alejandro Piscoya and Jose E. Vidal and Adrian V. Hernandez}, title = {Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials}, elocation-id = {2021.05.21.21257595}, year = {2021}, doi = {10.1101/2021.05.21.21257595}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background We systematically assessed benefits and harms of the use of ivermectin (IVM) in COVID-19 patients.Methods Published and preprint randomized controlled trials (RCTs) assessing IVM effects on COVID-19 adult patients were searched until March 15, 2021 in five engines. Primary outcomes were all-cause mortality, length of stay (LOS), and adverse events (AE). Secondary outcomes included viral clearance and severe AEs. We evaluated risk of bias (RoB) using the Cochrane RoB 2{\textperiodcentered}0 tool. Inverse variance random effect meta-analyses were performed with quality of evidence (QoE) evaluated using GRADE methodology. Subgroup analyses by severity of disease and RoB, and sensitivity analyses by time of follow-up were conducted.Results Ten RCTs (n=1173) were included. Controls were standard of care [SOC] in five RCTs and placebo in five RCTs. RCTs sample size ranged from 24 to 398 patients, mean age from 26 to 56 years-old, and severity of COVID-19 disease was mild in 8 RCTs, moderate in one RCT, and mild and moderate in one RCT. IVM did not reduce all-cause mortality vs. controls (RR 1.11, 95\%CI 0.16-7.65, very low QoE). IVM did not reduce LOS vs. controls (MD 0.72 days, 95\%CI -0.86 to 2.29, very low QoE). AEs, severe AE and viral clearance were similar between IVM and controls (low QoE for these three outcomes). Subgroup analyses by severity of COVID-19 disease or RoB were consistent with main analyses. Sensitivity analyses excluding RCTs with follow up \<21 days showed no difference in all-cause mortality but diminished heterogeneity (I2=0\%).Conclusions In comparison to SOC or placebo, IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease. IVM did not have effect on AEs or SAEs. IVM is not a viable option to treat COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics committee approval was necessary as this was a systematic review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data we used for this manuscript are available in text, tables, figures and supplementary file.}, URL = {https://www.medrxiv.org/content/early/2021/05/25/2021.05.21.21257595}, eprint = {https://www.medrxiv.org/content/early/2021/05/25/2021.05.21.21257595.full.pdf}, journal = {medRxiv} }